Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Outcomes of patients with CML receiving unmodified (n = 16) and CD34-selected (n = 24) allografts.

Data availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992;81:383–90. https://doi.org/10.1111/j.1365-2141.1992.tb08244.x.

    Article  CAS  PubMed  Google Scholar 

  2. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980–7.

    Article  CAS  PubMed  Google Scholar 

  3. Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol: Off J Am Soc Clin Oncol. 1999;17:561–8. https://doi.org/10.1200/JCO.1999.17.2.561.

    Article  CAS  Google Scholar 

  4. Elmaagacli AH, Peceny R, Steckel N, Trenschel R, Ottinger H, Grosse-Wilde H, et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2003;101:446–53. https://doi.org/10.1182/blood-2002-05-1615.

    Article  CAS  PubMed  Google Scholar 

  5. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E. et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–14. https://doi.org/10.7326/0003-4819-108-6-806.

    Article  CAS  PubMed  Google Scholar 

  6. Lubking A, Dreimane A, Sandin F, Isaksson C, Markevarn B, Brune M, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019;54:1764–74. https://doi.org/10.1038/s41409-019-0513-5.

    Article  CAS  PubMed  Google Scholar 

  7. Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, et al. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019;25:2008–16. https://doi.org/10.1016/j.bbmt.2019.06.028.

    Article  CAS  PubMed  Google Scholar 

  8. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022;40:356–68. https://doi.org/10.1200/JCO.21.02293.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: All authors. Data curation: JLV. Formal analysis: JLV and SB. Writing—Original Draft: JLV. Writing—Review and Editing: All Authors.

Corresponding author

Correspondence to Boglarka Gyurkocza.

Ethics declarations

Competing interests

SAG receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson, Inc., Actinium Pharmaceuticals, Inc., and is on the Advisory Boards for: Kite Pharmaceuticals, Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson, Inc., Amgen Inc., Takeda Pharmaceutical Co., Jazz Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc. MAP reports honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. BCS reports consulting for Hansa Biopharma and Gamida Cell. BG has received institutional research support for clinical trials from Actinium Pharmaceuticals.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vaughn, J.L., Brown, S., Papadopoulos, E.B. et al. CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era. Bone Marrow Transplant 57, 1740–1742 (2022). https://doi.org/10.1038/s41409-022-01783-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01783-7

Search

Quick links